Please login to the form below

enzalutamide

This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.

Bayer preps filings for new prostate cancer drug

If approved, darolutamide would become the third anti-androgen therapy to be licensed for men with this stage of prostate cancer after Pfizer/Astellas’ Xtandi (enzalutamide) and Johnson &Johnson’s Erleada

Latest news

EMA starts review of Xtandi in non-metastatic prostate cancer

Reported in February, the study showed that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease spreading or death by 71% compared with hormone therapy
J&J’s Erleada first US drug for non-metastatic prostate cancer

It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

The filings are based on the just-released results of the PROSPER trial, which show that adding Xtandi (enzalutamide) to treatment with anti-androgen hormone therapy reduced the risk of disease
Astellas extends phase III programme for Rydapt rival gilteritinib

Gilteritinib is one of a clutch of new drugs Astellas is banking on to inject renewed growth into its revenues as prostate cancer blockbuster Xtandi (enzalutamide) starts to slow down, and
Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

The US's largest drugmaker booked $141m from Xtandi (enzalutamide) in the second quarter, up from $131m in the first quarter of the year and flat on the last quarter of

More from news
Approximately 13 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Cost containment and the German market

The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Scientific Director / Editorial Team Leader: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Medical Writer: Great salary and benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Associate Medical Director: Highly Competitive

Account Director: Excellent benefits

Account Manager / Senior Account Manager: 35, 000-40, 000

New Business Director - PR: Competitive Salary and benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Executive, London, Medical Communications: Excellent package

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Medical Writers: Competitive Salary and Benefits

Consultant Health Economics - London / Oxford: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Associate Director: £75, 000-90, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Subscribe to our email news alerts

PMHub

Add my company

Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...